222 results on '"Schetelig, Johannes"'
Search Results
2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
6. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
9. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
10. Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation
11. The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation
12. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
13. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
14. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
15. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
16. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
17. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry
18. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML
19. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
20. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
21. Handling missing covariate data in clinical studies in haematology
22. Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions
23. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
24. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
25. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation
26. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
27. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
28. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
29. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
30. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
31. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
32. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
33. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
34. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy
35. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS
36. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
37. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
38. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
39. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma
40. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
41. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
42. The clinical mutatome of core binding factor leukemia
43. Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome
44. Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas
45. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
46. Haplotype reconstruction for genetically complex regions with ambiguous genotype calls: Illustration by the KIR gene region.
47. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies.
48. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
49. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
50. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.